the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis Panel; “Combined Multipurpose Prevention Strategies for Sexual and Reproductive Health”.

Date: October 18, 2011.

Time: 12:30 p.m. to 5 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, 6700B Rockledge Drive, Bethesda, MD 20817 (Telephone Conference Call).

Contact Person: Jane K. Battles, PhD, Scientific Review Officer, Scientific Review Program, Division of Extramural Activities, National Institutes of Health/NIAID, 6700B Rockledge Drive, Room 3147, Bethesda, MD 20892–7616, 301–451–2744, battlesja@mail.nih.gov.

Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis Panel; “Combined Multipurpose Prevention Strategies for Sexual and Reproductive Health”.

Date: October 31, 2011.

Time: 9 a.m. to 12 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, 6700B Rockledge Drive, Bethesda, MD 20817 (Telephone Conference Call).

Contact Person: Jane K. Battles, PhD, Scientific Review Officer, Scientific Review Program, Division of Extramural Activities, National Institutes of Health/NIAID, 6700B Rockledge Drive, Room 3147, Bethesda, MD 20892–7616, 301–451–2744, battlesja@mail.nih.gov.

(NAME OF COMMITTEE) (AGENCY) (DATE) (TIME) (PLACE) (CONTACT PERSON) (ACTION) (SUMMARY) (ADDITIONAL INFORMATION)

**ADDITIONAL INFORMATION:** The present invention provides compositions for making a medicament and methods for the administration of vaccine compositions for protection against human rotaviral disease without significant reactogenicity. Human x rhesus reassortant rotavirus compositions were made which when administered during the first 7 to about 10 days of life, provided a composition which was non-reactogenic followed by booster immunizations at 16 to 18 weeks or 14 to 20 weeks, up to 1 year of age. The immune response induced by the initial neonatal administration of the live rotavirus vaccine composition protects the infant from the reactivity of the composition when administered as a second vaccine dose at or after 2 months of age.

Administration of the immunogenic composition also is expected to ablate or significantly diminish the increase in the excess of intussusception observed 3 to 7 days following administration of the initial dose of rotavirus vaccine at about 2 to 4 months.

The prospective exclusive license will be royalty bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless within thirty (30) days from the date of this published notice, the NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.

Applications for a license in the field of use filed in response to this notice will be treated as objections to the grant of the contemplated exclusive license. Comments and objections submitted to this notice will not be made available for public inspection and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552.

Dated: September 22, 2011.

Richard U. Rodriguez,
Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.

[FR Doc. 2011–25098 Filed 9–28–11; 8:45 am]

**BILLING CODE 4140–01–P**

**DEPARTMENT OF HOMELAND SECURITY**

**Office of the Secretary**

[Docket No. DHS–2011–0076]

**DHS Data Privacy and Integrity Advisory Committee; Meeting**

**AGENCY:** Privacy Office, DHS.

**ACTION:** Notice.

**SUMMARY:** On Wednesday, September 21, 2011, the DHS Privacy Office announced in the Federal Register at 76 FR 58524 that the Data Privacy and...
DEPARTMENT OF HOMELAND SECURITY
Coast Guard
[Docket No. USCG–2011–0662]
Amendment of Marine Safety Manual, Volume III

AGENCY: Coast Guard, DHS.

ACTION: Notice of proposed policy change and request for comments.

SUMMARY: The Coast Guard is considering cancelling its policy concerning the issuance of Merchant Mariner Credentials endorsed as Able Seaman-Mobile Offshore Units (AB–MOU) endorsement. The policy is currently found in Chapter 16 of the Marine Safety Manual, Volume III. The Coast Guard will accept comments from the public on whether to cancel the policy and on any impacts the cancellation may have.

DATES: Comments and related material must either be submitted to our online docket via http://www.regulations.gov on or before October 31, 2011 or reach the Docket Management Facility by that date.

ADDRESSES: You may submit comments online by visiting the Docket Management Facility by that date. To view the “Read Comments” box, which will then become highlighted in blue. In the “Document Type” drop down menu, select “ Notices” and insert “USCG–2011–0662” in the “Keyword” box. Click “Search,” and then click on the balloon shape in the “Actions” column. If you submit your comments by mail or hand delivery, submit them in an unbound format, no larger than 8½; by 11 inches, suitable for copying and electronic filing. If you submit comments by mail and would like to know that they reached the Facility, please enclose a stamped, self-addressed postcard or envelope.

FOR FURTHER INFORMATION CONTACT: If you have questions about this notice, call or e-mail Luke B. Harden, Mariner Credentialing Program Policy Division (CG–5434), U.S. Coast Guard, telephone 202–322–2357, e-mail CG5434@uscg.mil. If you have questions on viewing material in the docket, call Renee V. Wright, Program Manager, Docket Operations, telephone 202–366–9826.

SUPPLEMENTARY INFORMATION:

Public Participation
You may submit comments and related material regarding whether to cancel the Able Seaman-Mobile Offshore Units (AB–MOU) endorsement. All comments received will be posted, without change, to http://www.regulations.gov and will include any personal information you have provided.

Submitting comments: If you submit a comment, please include the docket number for this notice (USCG–2011–0662) and provide a reason for each suggestion or recommendation. You may submit your comments and material online or by fax, mail or hand delivery, but please use only one of these means. We recommend that you include your name and a mailing address, an e-mail address, or a telephone number in the body of your document so that we can contact you if we have questions regarding your submission.

To submit your comment online, go to http://www.regulations.gov and click on the “submit a comment” box, which will then become highlighted in blue. In the “Document Type” drop down menu, select “ Notices” and insert “USCG–2011–0662” in the “Keyword” box. Click “Search,” and then click on the balloon shape in the “Actions” column. If you submit your comments by mail or hand delivery, submit them in an unbound format, no larger than 8½; by 11 inches, suitable for copying and electronic filing. If you submit comments by mail and would like to know that they reached the Facility, please enclose a stamped, self-addressed postcard or envelope.

We will consider all comments and material received during the comment period.

Viewing the comments: To view the comments, go to http://www.regulations.gov and click on the “Read Comments” box, which will then become highlighted in blue. In the “Keyword” box, insert “USCG–2011–0662” and click “Search.” Click the “Open Docket Folder” in the “Actions” column. If you do not have access to the internet, you may view the docket online by visiting the Docket Management Facility in Room W12–140 on the ground floor of the Department of Transportation West Building, 1200 New Jersey Avenue SE., Washington.